Hepatology Communications
Scope & Guideline
Fostering collaboration for a healthier liver future.
Introduction
Aims and Scopes
- Liver Disease Mechanisms and Pathophysiology:
Research exploring the cellular and molecular mechanisms underlying various liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hepatitis, and hepatocellular carcinoma (HCC). - Clinical Management and Therapeutics:
Studies focused on the clinical management strategies for liver diseases, including the effectiveness and safety of pharmacological treatments, surgical interventions, and emerging therapies. - Epidemiology and Public Health:
Research investigating the epidemiological trends, risk factors, and public health implications of liver diseases on a global scale. - Innovative Diagnostic Approaches:
Development and validation of novel diagnostic tools and biomarkers to enhance the detection and monitoring of liver diseases. - Patient-Centered Care and Quality of Life:
Investigations into how liver diseases affect patients' quality of life, including psychosocial aspects and health-related quality of life outcomes. - Translational Research and Experimental Models:
Utilization of experimental models and translational research approaches to understand liver pathophysiology and to develop new therapeutic strategies.
Trending and Emerging
- Metabolic Dysfunction-Associated Liver Disease (MASH/MASLD):
Research on metabolic dysfunction-associated steatotic liver disease is gaining traction, reflecting the increasing prevalence of obesity-related liver conditions. - Immunotherapy and Targeted Therapies:
There is a growing interest in the role of immunotherapy and targeted treatments for liver cancer, particularly hepatocellular carcinoma, highlighting advancements in personalized medicine. - Gut-Liver Axis Research:
Studies exploring the gut-liver axis, including the impact of gut microbiota on liver health and disease progression, are emerging as a significant area of investigation. - Digital Health and Telemedicine:
The integration of digital health technologies and telemedicine in liver disease management is on the rise, particularly in response to the COVID-19 pandemic. - Health Disparities and Social Determinants of Health:
Research addressing health disparities in liver disease, particularly among marginalized populations, is becoming increasingly prominent as awareness grows. - Artificial Intelligence and Machine Learning:
The application of AI and machine learning in diagnosing liver diseases and predicting outcomes is a rapidly growing area, reflecting technological advancements.
Declining or Waning
- Traditional Risk Factors for Liver Disease:
There appears to be a waning emphasis on traditional risk factors for liver disease, such as obesity and alcohol consumption, as newer studies focus on metabolic dysfunction and genetic predispositions. - Conventional Biomarker Studies:
Research centered on established biomarkers for liver disease is decreasing, as innovative diagnostic methods and multi-omics approaches gain prominence. - Single Disease Focus Studies:
There is a noticeable decline in studies that focus exclusively on single liver diseases; instead, there is a shift towards comprehensive studies that address multiple liver conditions and their interrelationships. - Invasive Diagnostic Procedures:
The use of invasive diagnostic procedures, such as liver biopsies, is decreasing in favor of non-invasive methods like elastography and blood-based biomarkers.
Similar Journals
JOURNAL OF HEPATOLOGY
Exploring Breakthroughs in Liver Disease ManagementJOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.
Journal of Clinical and Translational Hepatology
Advancing hepatology for better patient outcomes.Journal of Clinical and Translational Hepatology is an esteemed publication dedicated to advancing the field of hepatology through innovative research and clinical insights. Published by XIA & HE PUBLISHING INC, this journal connects researchers and healthcare professionals in the exploration of liver diseases and their management. With an impact factor that reflects its significant contribution to the discipline, the Journal holds a commendable Q2 classification in Hepatology as of 2023, and it ranks highly in both Gastroenterology and Hepatology categories on Scopus, positioning it within the top 80th percentile of its field. Although the journal is not open access, it provides its audience with invaluable information, encouraging collaboration that aims to translate clinical findings into transformative patient care. With a publication history spanning from 2013 to 2024, the Journal of Clinical and Translational Hepatology has established itself as a vital resource for researchers, clinicians, and students alike, making it a prominent voice in the hepatological community.
Gastrointestinal Disorders
Pioneering Research for a Healthier Digestive FutureGastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.
Journal of Clinical and Experimental Hepatology
Innovating hepatology: where clinical practice meets scientific discovery.The Journal of Clinical and Experimental Hepatology, published by Elsevier - Division Reed Elsevier India Pvt Ltd, is a premier platform dedicated to advancing the field of hepatology. With an ISSN of 0973-6883 and an E-ISSN of 2213-3453, this journal has gained recognition for its impactful contributions to both clinical practice and scientific research in the domain of liver health. Ranking in the Q2 quartile for Hepatology in 2023 and positioned at 33rd out of 82 in Scopus’s Hepatology category, it reflects a robust impact factor and a commitment to publishing high-quality, peer-reviewed articles. Researchers, clinicians, and students can engage with a wealth of open-access content covering the latest advancements, challenges, and insights in hepatology, as the journal aims to disseminate knowledge from 2011 through 2025. Join the community of experts as we explore critical developments in the understanding and treatment of liver diseases.
JHEP Reports
Leading the way in medical research dissemination.JHEP Reports, published by ELSEVIER, stands at the forefront of scholarly communication in the fields of Gastroenterology, Hepatology, Immunology and Allergy, and Internal Medicine. As an Open Access journal since 2019, it provides a platform for the dissemination of high-quality research findings, making vital information readily accessible to a global audience. With a commendable impact characterized by a Q1 category ranking across four medical disciplines in 2023, JHEP Reports demonstrates its significance and influence, reflected in its impressive Scopus ranks—#11 in Gastroenterology and #14 in Internal Medicine, amongst others. This esteemed journal not only plays a critical role in advancing knowledge but also fosters collaboration among researchers, practitioners, and students keen on exploring innovations and breakthroughs in health sciences. At RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, JHEP Reports is committed to bridging the gap between research and application, ushering in a new era of informed and effective healthcare solutions.
Journal of Gastrointestinal and Liver Diseases
Fostering Scholarly Excellence in Gastrointestinal ScienceThe Journal of Gastrointestinal and Liver Diseases, published by MEDICAL UNIV PRESS in Romania, serves as a pivotal platform for the dissemination of significant research in the fields of gastroenterology and hepatology. Established in 2006, this journal has evolved over the years, currently holding a Q3 rank in Gastroenterology and a Q2 rank in Medicine (miscellaneous), reflecting its commitment to high-quality scholarship and impactful contributions to medical science.
With an ISSN of 1841-8724 and an E-ISSN of 1842-1121, the journal engages a diverse readership of researchers, clinicians, and students passionate about advancing knowledge in gastrointestinal and liver health. While it currently does not operate under an open access model, the journal remains a vital resource for those seeking to stay updated on the latest developments and emerging trends in the field. As it converges towards a broader impact, projected through its coverage until 2024, the Journal of Gastrointestinal and Liver Diseases continues to contribute to the academic landscape, encouraging innovation and comprehensive understanding in digestive health.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
Elevating clinical practices through open access knowledge.REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, a pivotal Open Access journal published by ARAN EDICIONES, S A, has been at the forefront of advancing the field of gastroenterology since its inception in 1990. With a robust commitment to disseminating high-quality research, the journal provides a platform for researchers, clinicians, and students to share innovative findings and insights concerning digestive diseases. The journal is characterized by its Q3 ranking in both Gastroenterology and Miscellaneous Medicine categories, indicative of its significant contributions to these fields, and is positioned within the 36th percentile of Scopus rankings for medicine related to gastroenterology. Based in Spain, REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS has embraced the Open Access model since 2004, ensuring that its articles are readily available to a global audience without financial barriers. The journal not only supports academic discourse but also plays a crucial role in improving clinical practices and health outcomes related to digestive health.
LIVER INTERNATIONAL
Connecting researchers and practitioners in the fight against liver disease.LIVER INTERNATIONAL, with its ISSN 1478-3223 and E-ISSN 1478-3231, is a prestigious peer-reviewed journal published by Wiley in the United Kingdom. Established in 2003, it focuses on advancing the field of hepatology, covering a broad spectrum of topics including liver disease, hepatocellular carcinoma, and transplantation. Ranking #10 out of 82 in the Scopus category for Medicine - Hepatology and boasting a remarkable 88th percentile, LIVER INTERNATIONAL has secured its reputation as a leading journal, recognized as Q1 in the 2023 category quartiles. The journal emphasizes accessibility, offering an open access option to ensure that critical research findings reach a wider audience. By facilitating the dissemination of high-quality research, LIVER INTERNATIONAL plays a vital role in shaping contemporary hepatological discourse and bridging academic inquiry with clinical practice, making it an essential resource for researchers, healthcare professionals, and students alike.
World Journal of Hepatology
Elevating the discourse on liver health and disease management.World Journal of Hepatology is a premier academic journal dedicated to advancing the field of hepatology. Published by BAISHIDENG PUBLISHING GROUP INC, this journal serves as a crucial platform for disseminating innovative research findings and critical reviews from around the globe. With its ISSN 1948-5182 and E-ISSN 1948-5182, the journal has established a notable presence since its inception in 2009, covering a wide range of topics relevant to liver diseases, including but not limited to hepatitis, liver cancer, and metabolic liver disorders. Currently ranked 41/82 in the field of hepatology by Scopus, representing the 50th percentile, it has achieved a Q3 quartile ranking in the 2023 category, underscoring its growing influence in the medical community. With a commitment to open access for its readership, the World Journal of Hepatology enriches the global discourse on liver health and disease management, making it an essential resource for researchers, clinicians, and students alike.
HEPATOLOGY RESEARCH
Empowering global knowledge on liver disease and infections.Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.